OBJECTIVE: The M. D. Anderson Symptom Inventory (MDASI) captures the severity of common cancer symptoms from the patient's perspective. We describe the validity and sensitivity of a module of the MDASI to be used with patients having ovarian cancer (MDASI-OC). METHODS: Ovarian cancer-specific module items were developed from 14 qualitative patient interviews. 128 patients with invasive epithelial ovarian, peritoneal, or fallopian-tube cancer treated at The University of Texas MD Anderson Cancer Center were recruited. Patients completed the MDASI-OC, socio-demographic questionnaires, the Functional Assessment of Cancer Therapy-Ovary (FACT-O), and a global quality-of-life (QOL) item. Reliability was assessed using Cronbach α, and sensitivity using a known group was assessed. Construct validity was tested using exploratory factor analysis. RESULTS: The sample was primarily white (85.2%), had a mean age of 57.5 years (±12.7 years), and had previously been treated with chemotherapy (75.0%) and/or surgery (93.8%). Approximately 30% of patients reported disturbed sleep, fatigue, or numbness/tingling of at least moderate severity (≥5 on a 0-10 scale). On the ovarian-cancer-specific symptoms, approximately 20% reported back pain, feeling bloated, or constipation of at least moderate severity. Factor analysis revealed six underlying constructs (pain/sleep; cognitive; disease-related and numbness; treatment-related; affective; gastrointestinal-specific). MDASI-OC symptom and interference items had Cronbach α values of 0.90 and 0.89, respectively. The MDASI-OC was sensitive to symptom severity by performance status (p=0.009), QOL (p=0.002), and FACT-O scores (p<0.001). CONCLUSIONS: The 27-item MDASI-OC meets common criteria for validation and reliability and is sensitive to expected changes in symptoms related to differences in disease and treatment status.
OBJECTIVE: The M. D. Anderson Symptom Inventory (MDASI) captures the severity of common cancer symptoms from the patient's perspective. We describe the validity and sensitivity of a module of the MDASI to be used with patients having ovarian cancer (MDASI-OC). METHODS:Ovarian cancer-specific module items were developed from 14 qualitative patient interviews. 128 patients with invasive epithelial ovarian, peritoneal, or fallopian-tube cancer treated at The University of Texas MD Anderson Cancer Center were recruited. Patients completed the MDASI-OC, socio-demographic questionnaires, the Functional Assessment of Cancer Therapy-Ovary (FACT-O), and a global quality-of-life (QOL) item. Reliability was assessed using Cronbach α, and sensitivity using a known group was assessed. Construct validity was tested using exploratory factor analysis. RESULTS: The sample was primarily white (85.2%), had a mean age of 57.5 years (±12.7 years), and had previously been treated with chemotherapy (75.0%) and/or surgery (93.8%). Approximately 30% of patients reported disturbed sleep, fatigue, or numbness/tingling of at least moderate severity (≥5 on a 0-10 scale). On the ovarian-cancer-specific symptoms, approximately 20% reported back pain, feeling bloated, or constipation of at least moderate severity. Factor analysis revealed six underlying constructs (pain/sleep; cognitive; disease-related and numbness; treatment-related; affective; gastrointestinal-specific). MDASI-OC symptom and interference items had Cronbach α values of 0.90 and 0.89, respectively. The MDASI-OC was sensitive to symptom severity by performance status (p=0.009), QOL (p=0.002), and FACT-O scores (p<0.001). CONCLUSIONS: The 27-item MDASI-OC meets common criteria for validation and reliability and is sensitive to expected changes in symptoms related to differences in disease and treatment status.
Authors: Jeff A Sloan; Neil Aaronson; Joseph C Cappelleri; Diane L Fairclough; Claudette Varricchio Journal: Mayo Clin Proc Date: 2002-05 Impact factor: 7.616
Authors: E Greimel; A Bottomley; A Cull; A-C Waldenstrom; J Arraras; L Chauvenet; B Holzner; K Kuljanic; J Lebrec; S D'haese Journal: Eur J Cancer Date: 2003-07 Impact factor: 9.162
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Loretta A Williams; Sonika Agarwal; Diane C Bodurka; Angele K Saleeba; Charlotte C Sun; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2013-04-22 Impact factor: 3.612
Authors: Larissa A Meyer; Alpa M Nick; Qiuling Shi; Xin Shelley Wang; Loretta Williams; Tremaine Brock; Maria D Iniesta; Kelly Rangel; Karen H Lu; Pedro T Ramirez Journal: Gynecol Oncol Date: 2015-01-31 Impact factor: 5.482
Authors: Kavita D Chandwani; Fengmin Zhao; Gary R Morrow; Teresa L Deshields; Lori M Minasian; Judith Manola; Michael J Fisch Journal: J Pain Symptom Manage Date: 2017-02-06 Impact factor: 3.612
Authors: A Greco; E Orlandi; A Mirabile; S Takanen; C Fallai; N A Iacovelli; A Rimedio; E Russi; M Sala; D Monzani; D I Rosenthal; G B Gunn; P Steca; L Licitra; P Bossi Journal: Support Care Cancer Date: 2015-03-21 Impact factor: 3.603
Authors: Loretta A Williams; Meagan S Whisenant; Tito R Mendoza; Shireen Haq; Karen N Keating; Brian Cuffel; Charles S Cleeland Journal: Qual Life Res Date: 2018-09-05 Impact factor: 4.147
Authors: Larissa A Meyer; Javier Lasala; Maria D Iniesta; Alpa M Nick; Mark F Munsell; Qiuling Shi; Xin Shelley Wang; Katherine E Cain; Karen H Lu; Pedro T Ramirez Journal: Obstet Gynecol Date: 2018-08 Impact factor: 7.661
Authors: Yu Jung Kim; Mark F Munsell; Ji Chan Park; Larissa A Meyer; Charlotte C Sun; Alaina J Brown; Diane C Bodurka; Janet L Williams; Dana M Chase; Eduardo Bruera; Lois M Ramondetta Journal: Gynecol Oncol Date: 2015-09-30 Impact factor: 5.482